CRISPR Therapeutics CRSP Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's other operating expenses?
- CRISPR Therapeutics (CRSP) reported other operating expenses of $131.71M in Q1 2026.
- How has CRISPR Therapeutics's other operating expenses changed year-over-year?
- CRISPR Therapeutics's other operating expenses decreased by 11.8% year-over-year, from $149.29M to $131.71M.
- What is the long-term trend for CRISPR Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's other operating expenses has grown at a 5.4% compound annual growth rate (CAGR), from $541.44M to $668.08M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.